乳腺癌新辅助化疗对凋亡相关基因p53、bcl-2的影响

摘要

目的探讨乳腺癌新辅助化疗对凋亡相关基因p53、bcl-2表达的影响及其意义.方法用免疫组织化学ABC法检测97例新辅助化疗(研究组)和同期76例未行新辅助化疗(对照组)的乳腺癌组织p53、bcl-2蛋白的表达,并结合5年无病生存率(DFS)进行分析.结果研究组p53阳性率为28.9%(28/97),对照组为38.2%(29/76);研究组bcl-2阳性率为40.2%(39/97),对照组为56.7%(43/76);研究组5年DFS为74.2%(72/97),对照组为60.5%(46/76),两者比较均有显著差异.结论新辅助化疗通过凋亡相关基因p53、bcl-2的表达影响预后.%Objective To study the significance of neoadjuvant chemotherapy on p53/bcl -2 expression in breast cancer. Methods The study group which was treated with neoadjuvant chemotherapy (n = 97) and the control groupwhich did not accept neoadjuvant chemotherapy (n --79) were analyzed for expression of p53/bcl -2, and the DSF was also analyzed. Results p53 protein was expressed in 28 of 97 cases(28.9% ) in study group , while 29 of 76cases (38.2%) in control group;bcl-2 protein was expressed in 39 of 97 cases(40.2% ) in study group ,while 43of 76 cases(56.7% ) in control group;5 year - DFS in study group was 74.2% (72/79) ,while 60.5% (46/76) in control group. All the result was statistically significant. Conclusion It is possible that neoadjuvant chemotherapy can improve prognosis through adjusting expression of p53/bcl - 2.